First patient dosed in VAXINIA intratumoral cohort 2
Filed with ASX · · 3 pages · English
Story so far
Earlier from Imugene
- Preclinical trial of ALA iNKT therapy and IMU onCARlytics
- First patient IV dosed in VAXINIA Phase 1 clinical trial
- OGTR grants VAXINIA DIR licence allowing trial expansion
- Prospectus for the issue of institutional placement options
- Imugene announces a$80 million institutional placement
Later from Imugene
- Europe Patent granted for iNKT Cell Therapy Platform
- Imugene onCARlytics with blinatumomab SITC presentation
- Dose escalates In Phase I Clinical Trial of New Oncolytic Vi
- Imugene onCARlytics with Estrella ARTEMIS T Cells SITC
- First Patient Dosed in VAXINIA Intravenous Cohort 2
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene